Taysha Gene Therapies (NASDAQ:TSHA) Stock Rating Reaffirmed by Chardan Capital

Chardan Capital restated their buy rating on shares of Taysha Gene Therapies (NASDAQ:TSHA) in a report published on Tuesday morning, Benzinga reports. They currently have a $7.00 target price on the stock.

Other research analysts also recently issued reports about the company. JMP Securities reiterated a market outperform rating and set a $5.00 target price on shares of Taysha Gene Therapies in a research note on Wednesday, March 20th. Canaccord Genuity Group reiterated a buy rating and set a $7.00 target price on shares of Taysha Gene Therapies in a research note on Thursday, March 21st. Piper Sandler assumed coverage on Taysha Gene Therapies in a research note on Tuesday, April 9th. They set an overweight rating and a $9.00 target price for the company. Cantor Fitzgerald restated an overweight rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a research note on Tuesday, May 28th. Finally, Needham & Company LLC restated a buy rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a research note on Monday. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat, Taysha Gene Therapies presently has an average rating of Buy and an average target price of $7.00.

Taysha Gene Therapies Stock Performance

Shares of NASDAQ TSHA opened at $2.76 on Tuesday. The company has a current ratio of 3.38, a quick ratio of 3.38 and a debt-to-equity ratio of 0.75. Taysha Gene Therapies has a 12 month low of $0.50 and a 12 month high of $4.32. The stock has a 50 day moving average of $3.00 and a 200-day moving average of $2.38. The company has a market capitalization of $516.18 million, a P/E ratio of -5.63 and a beta of 0.50.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its earnings results on Tuesday, May 14th. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.01. Taysha Gene Therapies had a negative return on equity of 782.81% and a negative net margin of 833.60%. The company had revenue of $3.41 million during the quarter, compared to the consensus estimate of $3.70 million. During the same period in the previous year, the company posted ($0.28) EPS. As a group, equities research analysts predict that Taysha Gene Therapies will post -0.43 EPS for the current year.

Hedge Funds Weigh In On Taysha Gene Therapies

Institutional investors have recently modified their holdings of the business. Howard Capital Management Inc. acquired a new position in shares of Taysha Gene Therapies during the 4th quarter worth $25,000. Victory Capital Management Inc. acquired a new position in Taysha Gene Therapies in the 4th quarter worth about $28,000. Dynamic Technology Lab Private Ltd acquired a new position in Taysha Gene Therapies in the 4th quarter worth about $31,000. China Universal Asset Management Co. Ltd. acquired a new position in Taysha Gene Therapies in the 4th quarter worth about $38,000. Finally, Cannon Global Investment Management LLC acquired a new position in Taysha Gene Therapies in the 1st quarter worth about $69,000. Institutional investors and hedge funds own 77.70% of the company’s stock.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.